Analgesics & rebound headache
This article was originally published in The Tan Sheet
Executive Summary
Chronic use of OTC analgesics that can lead to "rebound headache" may be situation "where we need to improve the labeling and get better information out to consumers so that they can avoid the problem," FDA Commissioner Mark McClellan, MD/PhD, suggests during Jan. 15 appearance on National Public Radio's Diane Rehm Show. If consumers "are using the product very frequently for headaches, they probably should contact their health professional to see if there is another cause for the recurrent headaches, or if there is a better treatment available," he adds. McClellan's comments were prompted by article suggesting link between rebound headache and analgesic use in the Jan. 12 New York Times. Segment on the issue also aired on ABC TV's 20/20 program Jan. 10...
You may also be interested in...
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.
Marinomed Takes Virus-Blocking Device Into Allergy And Dry Eye Categories
Virus-blocking compound Carragelose, out-licensed to major consumer health players such as Perrigo and Reckitt for use in OTC respiratory nasal sprays, is being adapted for use in the dry eye and allergy categories.